Engflag

Gynotran Ovulo

Quick links to important sections

Gynotran Ovulo

Gynotran Ovulo_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gynotran Ovulo

Quick Facts

Property Description
Active ingredient Metronidazole and Miconazole nitrate
Form Vaginal ovule (Suppository capsule)
Pharmacological Class Gynecological Anti-infective and Antiseptic
Common Use Addresses complex vaginal infections
Origin Synthetic

Gynotran Ovulo: Definition and Pharmacological Classification

Gynotran Ovulo is a synthetic, prescription-only fixed-dose combination product classified as a gynecological anti-infective and antiseptic. This medication is often produced by the manufacturer Embil Ilac San. Ltd. Sti. and is available in various international markets.

The medication is composed of active substances belonging to two distinct pharmacological classes. It combines the nitroimidazole class agent Metronidazole with the azole antifungal agent Miconazole. The strategic combination of these two established compounds is clinically recognized for its ability to target the mixed nature of certain vaginal infections. This integrated approach simplifies treatment when both bacterial and fungal pathogens are present.

Composition and Drug Form: Why the Dual-Action Ovule?

Gynotran Ovulo contains two active pharmaceutical ingredients, Metronidazole and Miconazole nitrate, which are delivered via a specific dosage form known as a vaginal ovule. The ovule, a type of vaginal suppository capsule, utilizes an inert base that melts or dissolves at body temperature to ensure local administration.

The synthetic nature of both components enables the formulation to reliably deliver precise, fixed quantities of the anti-infective agents directly to the vaginal mucosa. Miconazole serves as the antifungal component, while Metronidazole provides the antibacterial and antiprotozoal activity. The local delivery system ensures that the therapeutic effect is focused exactly where it is needed, a characteristic that differentiates it from systemic treatments.

The General Purpose of This Combination Therapy

The overall purpose of Gynotran Ovulo is to provide comprehensive anti-infective coverage against complex or mixed vaginal infections, such as those that may involve organisms like Candida and Gardnerella species. The dual-action formula allows the medication to simultaneously target both fungal organisms (yeasts) and susceptible anaerobic bacteria or protozoa, ensuring a broad attack against the most common causative agents. This strategic dual mechanism is beneficial because it efficiently addresses the polymicrobial nature of many gynecological infections.

What side effects are possible with Gynotran Ovulo?

Possible side effects and safety information

The official safety information for the Metronidazole and Miconazole nitrate combination ovule outlines adverse reactions based on their frequency and the physiological systems affected, as classified in regulatory documents.

Adverse Reaction Frequencies

Side effects are categorized based on the likelihood of occurrence documented during clinical use and post-marketing surveillance:

  • Common Reactions (affecting 1 to 10 users in 100): These frequently documented effects typically involve the application site, including vaginal irritation, burning, pelvic cramps, and an increase in vaginal discharge. Systemic common effects can include headache and nausea.
  • Rare Reactions (affecting fewer than 1 in 1,000 users): Rarely reported but clinically significant adverse events include severe hypersensitivity reactions (allergic response), peripheral neuropathy, and blood disorders such as leukopenia (a reduction in white blood cells).

System-Organ Classes and Serious Safety Considerations

The documented adverse reactions may affect several system-organ classes, including the Reproductive System (local effects), Gastrointestinal System (e.g., metallic taste, abdominal pain), and the Nervous System (e.g., dizziness). The regulatory profile notes that rare but serious reactions, such as convulsive seizures and encephalopathy, are possible outcomes associated with high systemic exposure to the Metronidazole component.

Safety Restrictions and Special Populations

Official labeling includes specific safety limitations. The combination is restricted for use in individuals consuming alcohol during treatment and for at least three days after cessation, due to the risk of a disulfiram-like reaction. Caution is formally advised for patients with severe hepatic impairment, as the clearance of Metronidazole may be reduced. The use of the ovule is generally avoided during the first trimester of pregnancy based on regulatory notes for nitroimidazole compounds.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information addresses overdose risk primarily in the context of accidental oral ingestion of the vaginal ovule, which is considered an unlikely route of exposure. The documented consequences of overexposure are linked to the systemic effects of the Metronidazole component.

Documented Manifestations of Overdose

Symptoms officially documented in regulatory labels following acute overexposure include:

  • Gastrointestinal: Nausea, vomiting, abdominal pain, diarrhea, and anorexia.
  • Neurological: Vertigo, ataxia, paresthesia, headache, and severe outcomes like Convulsion (seizure).
  • Other: Metallic taste, itching, and leukopenia (low white blood cell count).

Immediate Actions Required

Regulators emphasize specific, required actions upon suspected overdose:

  • Seek Immediate Attention: If accidental oral ingestion of a dose much larger than normal is suspected, the user must contact an emergency room or a poison control center immediately.
  • Antidote Status: There is no specific antidote available for Metronidazole overexposure.

Overdose Management

Management is supportive and procedural. Symptomatic treatment is administered to manage clinical manifestations. Procedures such as gastric emptying or haemodialysis may be used to aid in the elimination of Metronidazole from the system. Patients with severe hepatic impairment require close monitoring, as the drug may accumulate due to slow metabolism.

Therapeutic Uses of Gynotran Ovulo

Targeting Complex and Mixed Vaginal Infections

This medication is generally used across conditions presenting with acute or disruptive episodes of mixed vaginal infections—conditions characterized by the co-existence of two or more distinct types of pathogens. It is relevant in contexts involving inflammatory or irritative processes associated with multiple organisms, such as Vulvovaginal Candidiasis, Bacterial Vaginosis, and Trichomonal Vaginitis. This comprehensive approach contributes to easing the overall symptom load and may be part of symptomatic management applied across domains where additional symptomatic support is needed.

Relief and Support for Symptom Clusters

Gynotran Ovulo is applied across domains where additional symptomatic support is needed. It helps to manage groups of symptoms that may become intense or disruptive, including pronounced vaginal itching (pruritus), vulvovaginal burning and irritation, and the presence of abnormal discharge and unpleasant odor. Addressing these physical manifestations provides support that helps ease the overall symptom burden, offering symptomatic relief that helps patients cope more steadily with difficult episodes. The combination formulation is commonly used across conditions presenting with recurrent or episodic manifestations.

Quick Fact: Context for Symptomatic Management Symptom Type Example Manifestation
Irritation Symptoms related to inflammatory or irritative states
Discharge Symptoms that interfere with daily functioning
Odor Symptoms that create noticeable physiological strain
Context Conditions involving episodic or fluctuating manifestations

Regulatory References

  1. FDA Verification Portal

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Regulatory documents strictly define who is eligible to use Gynotran Ovulo (Metronidazole and Miconazole ovule), focusing on absolute contraindications and population restrictions.

Populations Allowed and Restricted

Use is officially allowed only for adult females diagnosed with mixed vaginal infections. The medication is not recommended for use in children and adolescents, typically those under 18 years of age, or in women who are virgins.

In cases of pregnancy, Gynotran Ovulo is contraindicated during the first trimester. Use during the second and third trimesters is restricted and should occur only if clearly necessary. Breastfeeding is not recommended during therapy, requiring temporary cessation of nursing.

Patients with severe hepatic impairment or those requiring hemodialysis for severe renal impairment should use this medication with caution, and monitoring may be required.

Absolute Contraindications

Gynotran Ovulo must not be used by any patient with the following official exclusions:

  • Known hypersensitivity or allergy to metronidazole, miconazole, or any related nitroimidazole derivatives.
  • A history of blood dyscrasias or active central nervous system (CNS) disease.
  • Concurrent treatment with disulfiram or use within two weeks of stopping it.
  • Alcohol consumption during treatment and for a minimum of 24 to 72 hours following the final dose.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Although Gynotran Ovulo is administered vaginally, its metronidazole component is absorbed into the bloodstream and may interact with other medicines and products. Awareness of these interactions is essential, and patients should always inform their healthcare provider of all other concurrent treatments.

Interacting Product Category Specific Medicine Examples Interaction Detail & Management
Oral Anticoagulants Warfarin, other coumarin derivatives Metronidazole may enhance the anticoagulant effect, leading to a prolongation of prothrombin time (a measure of blood clotting). Close monitoring of Prothrombin Time and INR is required if these medicines are used together.
Alcohol / Propylene Glycol Alcoholic beverages A severe disulfiram-like reaction (including flushing, nausea, vomiting, and headaches) can occur. The consumption of alcohol or products containing propylene glycol must be discontinued during treatment and for at least three days after therapy completion.
Disulfiram Disulfiram Concurrent use is contraindicated. Metronidazole should not be used in patients who have taken disulfiram within the last two weeks due to the risk of psychotic reactions.
Lithium Lithium salts Oral metronidazole is associated with elevated serum lithium concentrations. Serum concentrations of lithium must be monitored when used concurrently with the metronidazole component.

It is also noted that the metronidazole component can potentially interfere with certain types of serum chemistry laboratory tests, such as those for AST, ALT, LDH, triglycerides, and glucose, potentially resulting in falsely lowered or zero values.

Mechanism of Action

The action of Gynotran Ovulo is defined by two complementary, targeted mechanisms resulting in the cellular destruction of susceptible pathogens. The combination provides distinct mechanisms of cellular damage across different classes of pathogens.

DNA Disruption via Anaerobic Activation

The Metronidazole component operates via selective toxicity, requiring bio-activation by low-redox-potential enzymes found only in susceptible anaerobic bacteria and protozoa. This process generates highly reactive free radicals that cause irreversible damage and breakage to the pathogen's DNA structure . This mechanism inhibits the pathogen's ability to synthesize essential nucleic acids, resulting directly in microbial cell death (bactericidal/trichomonacidal effect).

Fungal Cell Membrane Synthesis Blockade

Miconazole Nitrate acts by targeting the Ergosterol biosynthesis pathway, which is unique to fungi. It achieves this by inhibiting the fungal enzyme CYP51 (14alpha-lanosterol demethylase), a critical catalyst in sterol production. The resulting depletion of functional Ergosterol destabilizes the fungal cell membrane, causing leakage of cellular contents and leading to the structural breakdown and lysis of the fungal cell (fungicidal/fungistatic effect).

Dosage and Administration Information

The administration of the Metronidazole and Miconazole nitrate fixed-dose combination ovule is strictly defined by its local therapeutic purpose. The medication is designated for intravaginal use only, as it is a topical formulation intended to deliver the active ingredients directly to the site of infection, thereby avoiding high systemic exposure. The form contains a fixed quantity of Metronidazole 750 mg and Miconazole nitrate 200 mg per ovule, which defines the official dosage unit.

The standard administration pattern involves inserting one ovule into the vagina once daily for a required course duration of seven consecutive days. This 7-day cycle is the established duration for this specific fixed-dose regimen. For the once-daily application, the official administration time is commonly advised at bedtime. This timing is a procedural condition intended to facilitate maximum drug retention and consistency across the full treatment course.

It is a core administration constraint that the ovule must never be swallowed or used via an oral route. Furthermore, the full prescribed 7-day course must be adhered to, regardless of any early improvement in symptoms, to complete the standardized anti-infective protocol. Use of the ovule is generally not recommended for individuals under 18 years of age, though no specific dose adjustment is required for older adults.

Recent Clinical Evidence

Gynotran Ovulo: Recent Clinical Evidence

Gynotran Ovulo (a vaginal ovule or pessary) is a combination product containing Metronidazole (an antibacterial) and Miconazole Nitrate (an antifungal). This combination is used for treating vaginitis, a condition that may be caused by multiple microorganisms, including bacteria (like Gardnerella vaginalis), fungi (like Candida species), and parasites (Trichomonas vaginalis).

Clinical research, including Phase 3 trials, has explored the efficacy and tolerability of this specific formulation, typically containing 750 mg of Metronidazole and 200 mg of Miconazole Nitrate, applied once daily for seven days.

Key Findings from Clinical Studies

Studies focused on women diagnosed with vaginitis due to single or mixed infections. Outcome evaluation included assessment of symptoms and microbiological cure rates, which refers to the elimination of the specific pathogen(s) identified.

Research involving 92 women with vaginitis, including cases of candidiasis, bacterial vaginosis, and trichomoniasis, reported reductions in the clinical signs and symptoms of vaginitis. In one Phase 3 study, clinical cure was observed in approximately 87.7% of participants, while the microbiological cure rates varied by pathogen:

Infection Type (Pathogen) Microbiological Cure Rate (Approximate) Evaluation Timepoint
Bacterial Vaginosis (G. vaginalis) 75% Post-treatment
Vulvovaginal Candidiasis (C. albicans) 73.9% Post-treatment

Comparative and Safety Data

Clinical trials have also explored the compound’s performance compared to other standard treatments. For the treatment of bacterial vaginosis, one randomized controlled trial suggested that the metronidazole-miconazole ovule formulation demonstrated comparable cure rates and side effect profiles to a single high oral dose of metronidazole.

The overall safety profile was assessed in these trials, with studies reporting that adverse events were generally managed. Common adverse events reported in product information or trials include localized burning sensation, irritation at the application site, and allergic reactions.

Frequently Asked Questions (FAQ)

Common questions about Gynotran Ovulo (FAQ)

Q: How does Gynotran Ovulo get absorbed by the body?

Because this is a topical formulation, absorption into the body's bloodstream is generally limited. Studies indicate that the Metronidazole component has only about 20% bioavailability compared to the oral route. The absorption of Miconazole nitrate is very low and is typically not detectable in the blood plasma.

Q: Is there a list of ingredients in Gynotran Ovulo?

Yes, the official regulatory documents specify the drug's composition. These documents list the two active ingredients, Metronidazole and Miconazole nitrate. The ovule uses an inert base, generally described as a hard fat or hydrogenated vegetable oil, to help deliver the medication. The complete product information, including all inactive ingredients (excipients), is detailed in the full regulatory filing.

Q: What kind of infections are generally not treated by Gynotran Ovulo?

The dual-action formula of Gynotran Ovulo is intended for infections caused by susceptible fungi (yeasts), bacteria, and certain protozoa. Regulatory information indicates that the active ingredients do not target viruses. Therefore, based on the known pharmacological activity, the product is not indicated for the treatment of viral infections.

Q: What happens if a dose of Gynotran Ovulo is forgotten?

Official regulatory documents contain specific guidance regarding missed doses. This information typically describes how to proceed if a dose is forgotten and when to skip a dose to avoid doubling the amount used. This detailed guidance is found in the official patient information leaflet accompanying the medication.

Q: Can Gynotran Ovulo be used alongside probiotic supplements?

Official product warnings advise caution regarding the concurrent use of other vaginal products during the course of treatment. This guidance specifically cautions against the use of products such as douches, tampons, or certain other preparations while using the medication.

Q: Are there any restrictions on activity while using Gynotran Ovulo?

Official guidance associated with this class of topical treatments often includes restrictions on certain activities. Specifically, it is commonly advised against having vaginal intercourse during the full course of treatment with this type of ovule.

Q: Does Gynotran Ovulo affect latex condoms or diaphragms?

Yes, official warnings indicate that the ovule base contains a fat or oil that can damage materials such as latex. This may lead to the potential failure of latex condoms and diaphragms, reducing their effectiveness as contraceptive or protective devices.

How should Gynotran Ovulo be stored and disposed of?

Storage and Disposal of Gynotran Ovulo

The storage of Gynotran Ovulo is strictly governed by its official labeling to maintain product stability and efficacy. The medication must be kept in a cool, dry place and must not be stored above the regulatory limit of 30 C. Protection from direct light is mandatory, necessitating storage in the original package until the time of use.

Child Safety and Waste Management

For safety, the ovules must be kept out of the sight and reach of children. Regarding disposal, regulatory instructions state that expired or unused Gynotran Ovulo must not be discarded in household waste or flushed down the toilet. Instead, disposal must follow the local regulations and official collection channels established for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Gynotran Ovulo found in:

A-Z Index: